Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Atyr, Can-Fite, Eli Lilly, Humanigen, Immunic, Kyowa Kirin, Moderna, Neurorx, Oncoimmune, Opko Health, Opthea, Orpheris, Otsuka, Pluristem, Regeneron, Relief, Sinovac, Solasia, Tychan.
BEIJING – After his role as associate director and head of chemistry at Eli Lilly and Co., Brandeis-trained Jingye Zhou founded Eccogene Inc. in Shanghai in 2018 to focus on developing small-molecule drugs for metabolism and immune-related diseases.
LONDON – The foundation stone of a system to ensure equitable access to COVID-19 vaccines was put in place by the global vaccines summit on June 4, with 12 donors pledging $567 million in seed money for an advance market commitment (AMC) program.
HONG KONG – China’s Shanghai Junshi Biosciences Co. Ltd. has struck a deal with Merck KGaA for a clinical trial program in China to investigate the efficacy and safety of Junshi’s anti-PD-1 monoclonal antibody (MAb), Tuoyi (toripalimab) in combination with Merck’s Erbitux (cetuximab) as a treatment for recurrent and/or metastatic squamous cell carcinomas of the head and neck (SCCHN).
PERTH, Australia – Melbourne, Australia-based Dimerix Ltd. saw its shares gain 66% on the news that its lead candidate, DMX-200, has been chosen to enter the global REMAP-CAP platform trial as a potential treatment for COVID-19-related acute respiratory distress syndrome (ARDS).
PERTH, Australia – Aussie biotech CSL Ltd. and the University of Queensland (UQ) have entered a development agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) to accelerate development, manufacture and distribution of a COVID-19 vaccine candidate developed by the University of Queensland.
RSS
